Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00612,Bisoprolol
,2439789,absolute bioavailability,Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (greater than 90%) and small first-pass effect (10%).,Balanced pharmacokinetics and metabolism of bisoprolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),%,90,13263,DB00612,Bisoprolol
,2439789,plasma-elimination half-life,A long plasma-elimination half-life (10-11h) allows a once-a-day dose regimen.,Balanced pharmacokinetics and metabolism of bisoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),h,10-11,13264,DB00612,Bisoprolol
,22947502,flow rate,"Reverse-phase high performance liquid chromatography (RP-HPLC) separation was accomplished on a Diamonsil C(18) column (50mm×4.6mm, 5μm) with a mobile phase composed of methanol-water-formic acid (75:25:0.01, v/v/v) at a flow rate of 0.3mL/min.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),[ml] / [min],0.3,33867,DB00612,Bisoprolol
,22947502,total run time,The method had a chromatographic total run time of 3min.,Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),min,3,33868,DB00612,Bisoprolol
,22947502,m/,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,409,33869,DB00612,Bisoprolol
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,326.2,33870,DB00612,Bisoprolol
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,116.0,33871,DB00612,Bisoprolol
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,277.0,33872,DB00612,Bisoprolol
,22947502,m/z,"Multiple reacting monitoring (MRM) transitions of m/z [M+H](+) 409.1→237.9 (amlodipine), m/z [M+H](+) 326.2→116.0 (bisoprolol) and m/z [M+H](+) 277.0→203.0 (clenbuterol, IS) were used to quantify amlodipine, bisoprolol and IS, respectively.",Simultaneous determination of amlodipine and bisoprolol in rat plasma by a liquid chromatography/tandem mass spectrometry method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947502/),,203.0,33873,DB00612,Bisoprolol
,1683835,total apparent volume of distribution (Vz),"Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1).",Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683835/),,182,44916,DB00612,Bisoprolol
,1683835,total apparent volume of distribution (Vz),"Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1).",Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683835/),,1351,44917,DB00612,Bisoprolol
,1683835,Vz,"Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1).",Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683835/),1/[kg],2,44918,DB00612,Bisoprolol
,1683835,Vz,"Compared to the controls, the obese subjects showed an increase in the total apparent volume of distribution (Vz) (182 vs 1351) and a decrease in Vz per kg body weight (2 vs 2.71.kg-1).",Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683835/),1/[kg],2.71,44919,DB00612,Bisoprolol
,28577178,CL,"The typical mean value for bisoprolol CL, estimated by the base model, in the target population was 6.76 l/h.",Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577178/),[l] / [h],6.76,46119,DB00612,Bisoprolol
greater,2439779,FT4,Nine hyperthyroid patients (FT4 greater than or equal to 20 ng/L; FT3 greater than or equal to 6 ng/L) were given 1 X 10 mg bisoprolol/day p.o. for a period of 7 days.,Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [l],20,46495,DB00612,Bisoprolol
greater,2439779,FT3,Nine hyperthyroid patients (FT4 greater than or equal to 20 ng/L; FT3 greater than or equal to 6 ng/L) were given 1 X 10 mg bisoprolol/day p.o. for a period of 7 days.,Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [l],6,46496,DB00612,Bisoprolol
,2439779,maximum bisoprolol concentrations,"The maximum bisoprolol concentrations measured after the first dose and after 7 days were 54.3 +/- 2.1 and 70.3 +/- 3.8 ng/ml, respectively, the minimum concentrations being 9.6 +/- 1.0 ng/ml and 11.9 +/- 1.7 ng/ml, respectively.",Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [ml],54.3,46497,DB00612,Bisoprolol
,2439779,maximum bisoprolol concentrations,"The maximum bisoprolol concentrations measured after the first dose and after 7 days were 54.3 +/- 2.1 and 70.3 +/- 3.8 ng/ml, respectively, the minimum concentrations being 9.6 +/- 1.0 ng/ml and 11.9 +/- 1.7 ng/ml, respectively.",Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [ml],70.3,46498,DB00612,Bisoprolol
,2439779,minimum concentrations,"The maximum bisoprolol concentrations measured after the first dose and after 7 days were 54.3 +/- 2.1 and 70.3 +/- 3.8 ng/ml, respectively, the minimum concentrations being 9.6 +/- 1.0 ng/ml and 11.9 +/- 1.7 ng/ml, respectively.",Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [ml],9.6,46499,DB00612,Bisoprolol
,2439779,minimum concentrations,"The maximum bisoprolol concentrations measured after the first dose and after 7 days were 54.3 +/- 2.1 and 70.3 +/- 3.8 ng/ml, respectively, the minimum concentrations being 9.6 +/- 1.0 ng/ml and 11.9 +/- 1.7 ng/ml, respectively.",Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),[ng] / [ml],11.9,46500,DB00612,Bisoprolol
,2439779,accumulation factor,This yields an accumulation factor of 1.2.,Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),,1.2,46501,DB00612,Bisoprolol
,2439779,plasma elimination half-life,"At steady state, the plasma elimination half-life of bisoprolol was 9.8 +/- 0.9 h.",Pharmacokinetics of bisoprolol and influence on serum thyroid hormones in hyperthyroid patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439779/),h,9.8,46502,DB00612,Bisoprolol
,2887325,peak,"In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],52,47650,DB00612,Bisoprolol
,2887325,trough steady-state concentrations,"In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],11,47651,DB00612,Bisoprolol
,2887325,elimination half-life,"In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),h,10.0,47652,DB00612,Bisoprolol
,2887325,total body clearance,"In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[l] / [h],14.2,47653,DB00612,Bisoprolol
,2887325,half-life,"In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),h,18.5,47654,DB00612,Bisoprolol
,2887325,peak,"In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],74,47655,DB00612,Bisoprolol
,2887325,trough concentrations,"In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],32,47656,DB00612,Bisoprolol
,2887325,urinary excretion,"Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[mg] / [24·h],3.35,47657,DB00612,Bisoprolol
,2887325,total body clearance,"Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[l] / [h],7.8,47658,DB00612,Bisoprolol
,2887325,total clearance,In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours.,Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[l] / [h],5.0,47659,DB00612,Bisoprolol
,2887325,elimination half-life,In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours.,Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),h,24.2,47660,DB00612,Bisoprolol
,2887325,half-life,"In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),h,13.5,47661,DB00612,Bisoprolol
,2887325,steady-state peak,"In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],62,47662,DB00612,Bisoprolol
,2887325,trough concentrations,"In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[μg] / [l],22,47663,DB00612,Bisoprolol
,2887325,total body clearance,"In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h.",Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2887325/),[l] / [h],10.8,47664,DB00612,Bisoprolol
,1675817,plasma elimination half-life,Its pharmacokinetic profile appears extremely favourable with a plasma elimination half-life of about 10 h and a balanced clearance: bisoprolol is inactivated by liver metabolism (about 50%) and excreted unchanged in the urine (about 50%).,[Treatment of acute phase of myocardial infarction with injectable bisoprolol with oral versus]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675817/),h,10,55059,DB00612,Bisoprolol
,2439794,Faecal excretion,Faecal excretion was approximately 20% in rats and less than 10% in dogs and monkeys.,Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),%,20,63895,DB00612,Bisoprolol
less,2439794,Faecal excretion,Faecal excretion was approximately 20% in rats and less than 10% in dogs and monkeys.,Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),%,10,63896,DB00612,Bisoprolol
,2439794,plasma half-life,"The plasma half-life of the unchanged drug was approximately 1 h in rats, 3 h in monkeys, and 5 h in dogs.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),h,1,63897,DB00612,Bisoprolol
,2439794,plasma half-life,"The plasma half-life of the unchanged drug was approximately 1 h in rats, 3 h in monkeys, and 5 h in dogs.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),h,3,63898,DB00612,Bisoprolol
,2439794,plasma half-life,"The plasma half-life of the unchanged drug was approximately 1 h in rats, 3 h in monkeys, and 5 h in dogs.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),h,5,63899,DB00612,Bisoprolol
,2439794,bioavailability,"The bioavailability was 40-50% in monkeys, approximately 80% in dogs, and 10% in rats.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),%,40-50,63900,DB00612,Bisoprolol
,2439794,bioavailability,"The bioavailability was 40-50% in monkeys, approximately 80% in dogs, and 10% in rats.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),%,80,63901,DB00612,Bisoprolol
,2439794,bioavailability,"The bioavailability was 40-50% in monkeys, approximately 80% in dogs, and 10% in rats.",Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439794/),%,10,63902,DB00612,Bisoprolol
,15863897,CL/F,The mean CL/F value estimated with NONMEM was 0.0612.WT+1.15.,Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15863897/),,0.0612,78059,DB00612,Bisoprolol
,15863897,V/F,"CLcr (l/h), and the mean V/F value was 2.61.WT (l).",Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15863897/),l,2.61.,78060,DB00612,Bisoprolol
,2903820,oral bioavailability,"The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions.","Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903820/),%,90,81252,DB00612,Bisoprolol
,17418521,flow rate,"After alkalization with sodium hydroxide, the samples were extracted with ethyl acetate and separated by HPLC on a ZORBAX SB-C18 column with a mobile phase of 10 mM ammonium acetate buffer containing 0.1% formic acid-methanol (32:68, v/v) at a flow rate of 1 ml/min.",LC-ESI-MS method for the determination of bisoprolol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17418521/),[ml] / [min],1,82588,DB00612,Bisoprolol
,2878941,elimination half-lives,"After administering 20 mg of 14C-bisoprolol orally, mean elimination half-lives of 11 hours for the unchanged drug and 12 hours for total radioactivity were observed.","Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),h,11,86117,DB00612,Bisoprolol
,2878941,elimination half-lives,"After administering 20 mg of 14C-bisoprolol orally, mean elimination half-lives of 11 hours for the unchanged drug and 12 hours for total radioactivity were observed.","Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),h,12,86118,DB00612,Bisoprolol
,2878941,absolute bioavailability,Intraindividual comparison of the pharmacokinetic data measured after oral and intravenous administration of 10 mg bisoprolol to 12 subjects yielded an absolute bioavailability of 90%.,"Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),%,90,86119,DB00612,Bisoprolol
,2878941,Total,"Total and renal clearance were calculated as 15.6 L/hr and 9.6 L/hr, respectively.","Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),[l] / [h],15.6,86120,DB00612,Bisoprolol
,2878941,renal clearance,"Total and renal clearance were calculated as 15.6 L/hr and 9.6 L/hr, respectively.","Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),[l] / [h],9.6,86121,DB00612,Bisoprolol
,2878941,volume of distribution,The volume of distribution was 226 L.,"Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878941/),l,226,86122,DB00612,Bisoprolol
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB00612,Bisoprolol
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB00612,Bisoprolol
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB00612,Bisoprolol
,1983105,tissue/plasma concentration ratios,The highest tissue concentrations were observed in the iris (+ciliary body) and retina (+choroid) with tissue/plasma concentration ratios between 100 and 150 after oral and 1000 to 3000 after conjunctival instillation (5% solution).,Bisoprolol--comparative toxicokinetic study after oral and conjunctival administration in beagles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983105/),,100 and 150,94752,DB00612,Bisoprolol
,1983105,tissue/plasma concentration ratios,The highest tissue concentrations were observed in the iris (+ciliary body) and retina (+choroid) with tissue/plasma concentration ratios between 100 and 150 after oral and 1000 to 3000 after conjunctival instillation (5% solution).,Bisoprolol--comparative toxicokinetic study after oral and conjunctival administration in beagles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983105/),,1000 to 3000,94753,DB00612,Bisoprolol
,1983105,plasma half-life,In plasma no accumulation of the drug was observed which is in accordance with its plasma half-life of 4 to 5 h.,Bisoprolol--comparative toxicokinetic study after oral and conjunctival administration in beagles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983105/),h,4 to 5,94754,DB00612,Bisoprolol
,1983105,half-life,"In contrast to this, concentrations in the iris and retina increased from day 1 to day 16 and 30 by 3 to 8 times and the half-life of bisoprolol in these tissues was estimated to be between 3 to 5 days.",Bisoprolol--comparative toxicokinetic study after oral and conjunctival administration in beagles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1983105/),d,3 to 5,94755,DB00612,Bisoprolol
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],50.7,96241,DB00612,Bisoprolol
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],36.4,96242,DB00612,Bisoprolol
,17072092,systemic clearances,"Increased blood bisoprolol concentrations accompanied decreased mean systemic clearances: 50.7, 36.4, and 26.2 mL/min/kg in control, RAO, and BUL rats, respectively.",Pharmacokinetics and pharmacodynamics of bisoprolol in rats with bilateral ureter ligation-induced renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17072092/),[ml] / [kg·min],26.2,96243,DB00612,Bisoprolol
,34068544,Tmax,"F7 showed 1.9- and 2-fold higher values of Cmax and AUC0-40, respectively compared to Concor® tablets, as well as a smaller Tmax (2.00 ± 2.00 h).",Enhanced Transdermal Delivery of Bisoprolol Hemifumarate via Combined Effect of Iontophoresis and Chemical Enhancers: Ex Vivo Permeation/In Vivo Pharmacokinetic Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34068544/),h,2.00,106072,DB00612,Bisoprolol
,34068544,relative bioavailability,"The relative bioavailability of F7 was found to be 201.44%, relative to Concor® tablets, demonstrating the significantly enhanced transdermal permeation of BH from the selected hydrogel by iontophoresis, in human volunteers.",Enhanced Transdermal Delivery of Bisoprolol Hemifumarate via Combined Effect of Iontophoresis and Chemical Enhancers: Ex Vivo Permeation/In Vivo Pharmacokinetic Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34068544/),%,201.44,106073,DB00612,Bisoprolol
,2877885,peak plasma levels (Cssmax),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],55.5,108453,DB00612,Bisoprolol
,2877885,area under the plasma level-time curve (AUC tau),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],597,108454,DB00612,Bisoprolol
,2877885,total body clearance (CL),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],15.8,108455,DB00612,Bisoprolol
,2877885,elimination half-lives (t1/2 beta),"After therapy with bisoprolol alone peak plasma levels (Cssmax) of the beta-blocker were 55.5 +/- 6.4 ng/ml (means +/- SEM), area under the plasma level-time curve (AUC tau) was 597 +/- 70 ng/ml.h, total body clearance (CL) 15.8 +/- 1.8 l/h and elimination half-lives (t1/2 beta) 10.1 +/- 1.2 h.",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,10.1,108456,DB00612,Bisoprolol
,2877885,Cssmax,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [ml],43.0,108457,DB00612,Bisoprolol
,2877885,AUC tau,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[ng] / [h·ml],397,108458,DB00612,Bisoprolol
,2877885,t1/2 beta,"Co-administration of rifampicin resulted in a decrease in Cssmax (43.0 +/- 6.9 ng/ml), AUC tau (397 +/- 54 ng/ml X h) and t1/2 beta (6.2 +/- 0.4 h).",Interaction of bisoprolol with cimetidine and rifampicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),h,6.2,108459,DB00612,Bisoprolol
,2877885,total body clearance,"Accordingly, total body clearance increased to 23.8 +/- 2.5 l/h (p less than 0.05).",Interaction of bisoprolol with cimetidine and rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877885/),[l] / [h],23.8,108460,DB00612,Bisoprolol
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],1.5-2.0,109392,DB00612,Bisoprolol
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],2.5,109393,DB00612,Bisoprolol
,11549204,PRA,"PRA increased significantly following I alone (1.5-2.0 ng/ml/h), as well as combined with N (2.5 ng/ ml/h) or H (3.1 ng/ml/h).","Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549204/),[ng] / [h·ml],3.1,109394,DB00612,Bisoprolol
,22553280,flow rate,"Chromatographic separation of bisoprolol was achieved by using isocratic elution at a flow rate of 1.2 mL/min on a C18 reversed-phase column (Inertsil, 4 μm, 150 4.6 mm) at 40°C.",An HPLC method for the determination of bisoprolol in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22553280/),[ml] / [min],1.2,116796,DB00612,Bisoprolol
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[μg] / [cm(2)h],7.4,123504,DB00612,Bisoprolol
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[μg] / [cm(2)h],5.9,123505,DB00612,Bisoprolol
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,33.6,123506,DB00612,Bisoprolol
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,31.3,123507,DB00612,Bisoprolol
,2904825,elimination half-life,"3. Examination of the pharmacokinetic data showed that bisoprolol had a median elimination half-life of 11.2 h during chronic dosing, compared with 6.4 h for atenolol.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),h,11.2,135147,DB00612,Bisoprolol
,2904825,elimination half-life,"3. Examination of the pharmacokinetic data showed that bisoprolol had a median elimination half-life of 11.2 h during chronic dosing, compared with 6.4 h for atenolol.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),h,6.4,135148,DB00612,Bisoprolol
,2904825,clearance,"For bisoprolol, the median clearance fell from 264 ml min-1 after a single dose to 212 ml min-1 during chronic dosing, although clinically significant accumulation would not be expected during chronic administration.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),[ml] / [min],264,135149,DB00612,Bisoprolol
,2904825,clearance,"For bisoprolol, the median clearance fell from 264 ml min-1 after a single dose to 212 ml min-1 during chronic dosing, although clinically significant accumulation would not be expected during chronic administration.",A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2904825/),[ml] / [min],212,135150,DB00612,Bisoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,326.2,146028,DB00612,Bisoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,116.1,146029,DB00612,Bisoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,268.2,146030,DB00612,Bisoprolol
,17324642,m/z,The mass transition ion-pair was followed as m/z 326.2-->116.1 for bisoprolol and m/z 268.2-->191.0 for metoprolol.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),,191.0,146031,DB00612,Bisoprolol
,17324642,overall recoveries,"The overall recoveries for bisoprolol and metoprolol were 93.89% and 77.65%, respectively.",A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),%,93.89,146032,DB00612,Bisoprolol
,17324642,overall recoveries,"The overall recoveries for bisoprolol and metoprolol were 93.89% and 77.65%, respectively.",A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),%,77.65,146033,DB00612,Bisoprolol
,17324642,Total MS run time,Total MS run time was 0.90 min only.,A high throughput and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of bisoprolol in human plasma using multiplexing technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324642/),min,0.90,146034,DB00612,Bisoprolol
,2568209,volume of central compartment,"The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively.",Population pharmacokinetic analysis of bisoprolol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),l,68,146122,DB00612,Bisoprolol
,2568209,volume of distribution at steady-state,"The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively.",Population pharmacokinetic analysis of bisoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),l,235,146123,DB00612,Bisoprolol
,2568209,volume of distribution at steady-state,"The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively.",Population pharmacokinetic analysis of bisoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),1/[h],0.7,146124,DB00612,Bisoprolol
,2568209,volume of distribution at steady-state,"The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively.",Population pharmacokinetic analysis of bisoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),l,28,146125,DB00612,Bisoprolol
,2568209,volume of distribution at steady-state,"The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively.",Population pharmacokinetic analysis of bisoprolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),l,55,146126,DB00612,Bisoprolol
,2568209,clearance,"The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I.",Population pharmacokinetic analysis of bisoprolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),[l] / [h],8.2 to 21.5,146127,DB00612,Bisoprolol
,2568209,elimination half-life,"The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I.",Population pharmacokinetic analysis of bisoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568209/),h,7.6 to 19.7,146128,DB00612,Bisoprolol
,25660911,enhancing ratio (ER),"Then, to simultaneously up-regulate the amounts of the two drugs, an enhancer combination of 15.8% Span80 (SP), 6.0% Azone (AZ) and 2.2% N-methyl pyrrolidone (NMP) was obtained by central composite design and exhibited an outstanding and simultaneous enhancement on IND and BSP with enhancing ratio (ER) of 4.52 and 3.49, respectively.",Dual-directional regulation of drug permeating amount by combining the technique of ion-pair complexation with chemical enhancers for the synchronous permeation of indapamide and bisoprolol in their compound patch through rabbit skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660911/),,4.52,156820,DB00612,Bisoprolol
,25660911,enhancing ratio (ER),"Then, to simultaneously up-regulate the amounts of the two drugs, an enhancer combination of 15.8% Span80 (SP), 6.0% Azone (AZ) and 2.2% N-methyl pyrrolidone (NMP) was obtained by central composite design and exhibited an outstanding and simultaneous enhancement on IND and BSP with enhancing ratio (ER) of 4.52 and 3.49, respectively.",Dual-directional regulation of drug permeating amount by combining the technique of ion-pair complexation with chemical enhancers for the synchronous permeation of indapamide and bisoprolol in their compound patch through rabbit skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25660911/),,3.49,156821,DB00612,Bisoprolol
,22418070,run time,"Separation was performed on a TC-C₁₈ column (150 mm × 4.6 mm, 5 μm) using a mobile phase of methanol:10 mM ammonium acetate containing 1% formic acid (65:35, v/v) in a run time of 3.5 min.","Determination of landiolol, an ultra-short-acting β₁-receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22418070/),min,3.5,167348,DB00612,Bisoprolol
,23093041,clearance (CL),"The typical mean value for bisoprolol clearance (CL), estimated by the base model (without covariates), in our population was 11.4 l h(-1).",Population pharmacokinetics of bisoprolol in patients with chronic heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093041/),[l] / [h],11.4,189357,DB00612,Bisoprolol
,19046015,area under the concentration-time curve extrapolated to infinity (AUCinf),"After oral administration of bisoprolol, the geometric mean value of the area under the concentration-time curve extrapolated to infinity (AUCinf) was 2,195 microg/L (coefficient of variation [CV], 15%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],"2,195",197509,DB00612,Bisoprolol
,19046015,AUCinf,"After IV administration of bisoprolol, the dose-normalized geometric mean AUCinf was 2,402 microg/L (CV, 19%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],"2,402",197510,DB00612,Bisoprolol
,19046015,Oral bioavailability,Oral bioavailability of bisoprolol was 91.4%.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),%,91.4,197511,DB00612,Bisoprolol
,19046015,AUCinf,"After oral administration of carvedilol, the geometric mean AUCinf was 70 microg/L (CV, 81%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],70,197512,DB00612,Bisoprolol
,19046015,AUCinf,"After IV administration of carvedilol, the geometric mean AUCinf was 491 microg/L (CV, 23%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],491,197513,DB00612,Bisoprolol
,19046015,Oral bioavailability,Oral bioavailability of carvedilol was 14.3%.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),%,14.3,197514,DB00612,Bisoprolol
,19046015,Total body clearance,Total body clearance was low (0.42 L/h/kg) for bisoprolol and high (2.0 L/h/kg) for carvedilol.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[l] / [h·kg],0.42,197515,DB00612,Bisoprolol
,19046015,Total body clearance,Total body clearance was low (0.42 L/h/kg) for bisoprolol and high (2.0 L/h/kg) for carvedilol.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[l] / [h·kg],2.0,197516,DB00612,Bisoprolol
,1888640,elimination half-life,3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH).,The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888640/),h,8.6,199346,DB00612,Bisoprolol
,1888640,elimination half-life,3. In the first NA experiment NA 7CH significantly shortened the elimination half-life of NA from 8.6 +/- 2.2 (placebo) to 6.4 +/- 1.6 h (NA 7CH).,The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888640/),h,6.4,199347,DB00612,Bisoprolol
,20922637,heart rate,The heart rate reflected a value of 98 beats per minute.,[Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20922637/),[beats] / [min],98,214475,DB00612,Bisoprolol
,9523980,S/R ratio,"The metabolic clearance of (R)-(+)-bisoprolol was significantly (P < 0.05) larger than that of (S)-(-)-bisoprolol (S/R ratio: 0.79+/-0.03), although the difference was small.",Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523980/),,0.,216061,DB00612,Bisoprolol
,9523980,S/R ratio,"The S/R ratio of the mean clearance due to renal tubular secretion was 0.68, indicating a moderate degree of stereoselective renal tubular secretion.",Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523980/),,0.68,216062,DB00612,Bisoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],72,234919,DB00612,Bisoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],87,234920,DB00612,Bisoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],44,234921,DB00612,Bisoprolol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],0.2,234922,DB00612,Bisoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],167,234923,DB00612,Bisoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],114,234924,DB00612,Bisoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],96,234925,DB00612,Bisoprolol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],24,234926,DB00612,Bisoprolol
,26639509,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) and the time to reach it (T(max)) were 409.5 ng/ml and 3.6 min for the BF nasal spray, 39.4 ng/ml and 26.7 min for the drug solution, respectively.",Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639509/),[ng] / [ml],409.5,245024,DB00612,Bisoprolol
,26639509,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) and the time to reach it (T(max)) were 409.5 ng/ml and 3.6 min for the BF nasal spray, 39.4 ng/ml and 26.7 min for the drug solution, respectively.",Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639509/),[ng] / [ml],39.4,245025,DB00612,Bisoprolol
,26639509,time to reach it (T(max)),"The maximum plasma concentration (C(max)) and the time to reach it (T(max)) were 409.5 ng/ml and 3.6 min for the BF nasal spray, 39.4 ng/ml and 26.7 min for the drug solution, respectively.",Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639509/),min,3.6,245026,DB00612,Bisoprolol
,26639509,time to reach it (T(max)),"The maximum plasma concentration (C(max)) and the time to reach it (T(max)) were 409.5 ng/ml and 3.6 min for the BF nasal spray, 39.4 ng/ml and 26.7 min for the drug solution, respectively.",Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639509/),min,26.7,245027,DB00612,Bisoprolol
greater,26639509,bioavailability,The bioavailability of the BF nasal spray was greater than 1500.0%.,Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639509/),%,1500.0,245028,DB00612,Bisoprolol
,26996442,clearance,Mean bisoprolol clearance (10.2 L/h) was 30 % lower than in healthy individuals and correlated with MDRD4-estimated renal function.,Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),[l] / [h],10.2,246924,DB00612,Bisoprolol
,26996442,volume of distribution,The mean volume of distribution (230 L) was similar to healthy population and was associated with total body mass and skeletal muscle index (SMI).,Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),l,230,246925,DB00612,Bisoprolol
,26996442,absorption rate constant,"During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant.",Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),1/[h],2.83,246926,DB00612,Bisoprolol
,26996442,absorption rate constant,"During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant.",Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),1/[h],2.27,246927,DB00612,Bisoprolol
,26996442,volume of distribution,"During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant.",Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),l,227,246928,DB00612,Bisoprolol
,26996442,volume of distribution,"During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant.",Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26996442/),l,250,246929,DB00612,Bisoprolol
,1970298,plasma elimination half-life (t1/2),The mean plasma elimination half-life (t1/2) increased from 12.9 to 13.2 h during steady state on bisoprolol and from 7.2 to 11.5 h on atenolol.,A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),h,12.9 to 13.2,247472,DB00612,Bisoprolol
,1970298,plasma elimination half-life (t1/2),The mean plasma elimination half-life (t1/2) increased from 12.9 to 13.2 h during steady state on bisoprolol and from 7.2 to 11.5 h on atenolol.,A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),h,7.2 to 11.5,247473,DB00612,Bisoprolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,235,247474,DB00612,Bisoprolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,146,247475,DB00612,Bisoprolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,216,247476,DB00612,Bisoprolol
,1970298,apparent volume of distribution (Vz),"The apparent volume of distribution (Vz) was greater for bisoprolol than for atenolol after single dosing (235 1 vs 146 1) and at steady state (216 1 vs 137 1), but clearances were similar for both drugs.",A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970298/),1,137,247477,DB00612,Bisoprolol
,24607107,flow rate,"The chromatographic separation was achieved on a reversed phase C18 column with a mobile phase of acetonitrile: 0.1% diethyl amine (pH 3.5) (60:40, v/v) pumped at a flow rate of 1.0 mL min(-1).",Validated liquid chromatographic-fluorescence method for the quantitation of darifenacin in mice plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24607107/),[ml] / [min],1.0,252176,DB00612,Bisoprolol
,12474215,Retention times,"Retention times for bisoprolol and metoprolol were 8.7 and 3.2 min, respectively.","Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),min,8.7,255292,DB00612,Bisoprolol
,12474215,Retention times,"Retention times for bisoprolol and metoprolol were 8.7 and 3.2 min, respectively.","Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),min,3.2,255293,DB00612,Bisoprolol
,12474215,recovery,Average recovery was 89% for metoprolol and 98% for bisoprolol.,"Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),%,89,255294,DB00612,Bisoprolol
,12474215,recovery,Average recovery was 89% for metoprolol and 98% for bisoprolol.,"Development, validation and analytical error function of two chromatographic methods with fluorimetric detection for the determination of bisoprolol and metoprolol in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12474215/),%,98,255295,DB00612,Bisoprolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,4.8,274170,DB00612,Bisoprolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,6.87,274171,DB00612,Bisoprolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,9.19,274172,DB00612,Bisoprolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],220,274173,DB00612,Bisoprolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],904,274174,DB00612,Bisoprolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],445,274175,DB00612,Bisoprolol
